Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy

In 1997, for the first time in history, a monoclonal antibody (mAb), i.e., the chimeric anti-CD20 molecule rituximab, was approved by the US Food and Drug Administration for use in cancer patients. Since then, the panel of mAbs that are approved by international regulatory agencies for the treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Vacchelli, Erika, Aranda, Fernando, Eggermont, Alexander, Galon, Jérôme, Sautès-Fridman, Catherine, Zitvogel, Laurence, Kroemer, Guido, Galluzzi, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937194/
https://www.ncbi.nlm.nih.gov/pubmed/24605265
http://dx.doi.org/10.4161/onci.27048

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3937194/
https://www.ncbi.nlm.nih.gov/pubmed/24605265
http://dx.doi.org/10.4161/onci.27048

Ejemplares similares